Literature DB >> 24228113

Systemic mesenchymal stem cells reduce growth rate of cisplatin-resistant ovarian cancer.

Pengfei Zhu1, Mo Chen, Li Wang, Yanxia Ning, Jie Liang, Hao Zhang, Congjian Xu, Sifeng Chen, Liangqing Yao.   

Abstract

Epithelial ovarian cancer is one of the most malignant cancers in women and resistant to chemotherapy is the major obstacle for the five-year survival rate. Cisplatin is one of the effective anticancer drug used in the ovarian cancer. To find a good strategy to cure the tumors which is resistant to cisplatin, the cisplatin-resistant 3SKOV3 cells were selected from SKOV-3 ovarian cancer cells. Furthermore, the isolated mesenchymal stem cells were infused systemically to try to cure the transplanted tumor induced by 3SKOV3 cells in nude mice. The morphology and cell membrane CD44 expression were investigated by microscope and flow cytometry. The biological behaviors of resistant 3SKOV3 and its parental SKOV3 cells, including proliferation, adhesion, and cell cycle were determined by CCK8, absorbance assay and FCM methods. The transplanted tumors were set up in nude mice with 3SKOV3 cells injection. The growth rate of transplanted tumors was detected following with MSCs injection. The 3SKOV3 cells have different morphologic manifestation and expressed high level of CD44 molecule. At the same time, 3SKOV3 cells have less adhesion ability and less S-phase ratio. The isolated MSCs from bone marrow could inhibit the growth of transplanted tumor via systemic injection. The cisplatin-resistant 3SKOV3 cells have the different biological behaviors as its parental SKOV3 cells. The present study indicated that systemic MSCs have the therapeutic role on ovarian cancer. However, further investigations are in progress to elucidate the underlying mechanism.

Entities:  

Keywords:  Cisplatin; mesenchymal stem cells; nude mice; ovarian cancer; resistance

Mesh:

Substances:

Year:  2013        PMID: 24228113      PMCID: PMC3816820     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  22 in total

Review 1.  Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets?

Authors:  R M Dwyer; M J Kerin
Journal:  Hum Gene Ther       Date:  2010-10-06       Impact factor: 5.695

2.  Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Bobbie S Gostout; Monica B Jones; C Robert Stanhope; Timothy O Wilson; Karl C Podratz; William A Cliby
Journal:  Obstet Gynecol       Date:  2006-01       Impact factor: 7.661

Review 3.  Latest research and treatment of advanced-stage epithelial ovarian cancer.

Authors:  Robert L Coleman; Bradley J Monk; Anil K Sood; Thomas J Herzog
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

Review 4.  Mesenchymal stem cells at the intersection of cell and gene therapy.

Authors:  Timothy J Myers; Froilan Granero-Molto; Lara Longobardi; Tieshi Li; Yun Yan; Anna Spagnoli
Journal:  Expert Opin Biol Ther       Date:  2010-12       Impact factor: 4.388

5.  Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes.

Authors:  Miaoxin Lin; Xiaoyong Wang; Jianhui Zhu; Damin Fan; Yangmiao Zhang; Junfeng Zhang; Zijian Guo
Journal:  Apoptosis       Date:  2011-03       Impact factor: 4.677

Review 6.  Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.

Authors:  Christian Kurzeder; Georg Sauer; Helmut Deissler
Journal:  Curr Cancer Drug Targets       Date:  2006-05       Impact factor: 3.428

Review 7.  Non platinum metal complexes as anti-cancer drugs.

Authors:  Ingo Ott; Ronald Gust
Journal:  Arch Pharm (Weinheim)       Date:  2007-03       Impact factor: 3.751

8.  Intravenous administration of bone marrow mesenchymal stromal cells is safe for the lung in a chronic myocardial infarction model.

Authors:  Wei Wang; Qin Jiang; Hao Zhang; Peifeng Jin; Xin Yuan; Yingjie Wei; Shengshou Hu
Journal:  Regen Med       Date:  2011-03       Impact factor: 3.806

Review 9.  The utility of cells as vehicles for oncolytic virus therapies.

Authors:  Stephen J Russell; Kah Whye Peng
Journal:  Curr Opin Mol Ther       Date:  2008-08

10.  Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas.

Authors:  R E Meyn; L C Stephens; N R Hunter; L Milas
Journal:  Int J Cancer       Date:  1995-03-03       Impact factor: 7.396

View more
  5 in total

Review 1.  The Clinical Applications of Endometrial Mesenchymal Stem Cells.

Authors:  Wanyun Zuo; Bingyu Xie; Chenglong Li; Yuhan Yan; Yangyi Zhang; Wei Liu; Jufang Huang; Dan Chen
Journal:  Biopreserv Biobank       Date:  2017-12-21       Impact factor: 2.300

2.  Human endometrial mesenchymal stem cells exhibit intrinsic anti-tumor properties on human epithelial ovarian cancer cells.

Authors:  Shixia Bu; Qian Wang; Qiuwan Zhang; Junyan Sun; Biwei He; Charlie Xiang; Zhiwei Liu; Dongmei Lai
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

Review 3.  Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies.

Authors:  Jacek R Wilczyński; Miłosz Wilczyński; Edyta Paradowska
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 5.923

4.  Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer.

Authors:  Irma Virant-Klun; Natasa Kenda-Suster; Spela Smrkolj
Journal:  J Ovarian Res       Date:  2016-03-03       Impact factor: 4.234

Review 5.  Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled.

Authors:  Yuliya Klymenko; Kenneth P Nephew
Journal:  Cancers (Basel)       Date:  2018-08-30       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.